Navigation Links
Oxford Finance Closes $20 Million Debt Facility with Inhibrx

ALEXANDRIA, Va., April 9, 2015 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan agreement with Inhibrx, a biologic immunotherapeutic company focused on the treatment of unmet medical needs in oncology, infectious disease and inflammatory conditions. Proceeds of the loan will enable Inhibrx to continue to advance its extensive portfolio of therapeutics.

"We are pleased to provide financing to Inhibrx to support the development of their therapeutic pipeline addressing various clinical targets," said Christopher A. Herr, managing director for Oxford Finance. "The company currently has a promising licensing agreement with a major biopharmaceutical company for one of its assets, and has a unique business model that enables a cost effective and accelerated process for advancing other therapeutics into the clinic."

"We appreciate Oxford's support of our efforts to develop innovative therapeutics for patients in need of better treatment options," said Mark Lappe, chief executive officer of Inhibrx.

About Oxford Finance LLC

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $2 billion in loans, with lines of credit ranging from $500 thousand to $75 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit

About Inhibrx

Inhibrx is a biologic immunotherapeutic company focused on the treatment of unmet medical needs. Inhibrx's proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation and mediate enhanced signaling.  Inhibrx's first immuno-oncology therapeutic is a highly differentiated antibody targeting CD47.  This mAb was licensed by Celgene and entered clinical studies in early 2015.  Inhibrx expects to bring ten therapeutics into clinical trials in 2016 and 2017 for oncology, infectious disease and inflammatory conditions. For more information visit

SOURCE Oxford Finance LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Performance Materials and Biomet Microfixation Join Forces
2. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
3. Oxford BioMedica Announces Update from ARVO 2013
4. Oxford University Press to publish BioScience journal starting in 2014
5. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
6. Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up
7. Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston
8. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
9. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
10. Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
11. ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria
Post Your Comments:
(Date:7/10/2020)... (PRWEB) , ... July 09, ... ... biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has expanded ... broader license allows PathSensors to move into the point-of-care diagnostic market, focusing ...
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
(Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal Purchasing System ... its membership, recently named BioFit Engineered Products an Awarded Vendor. Awarded ... ergonomic seating, cafeteria tables, book trucks and carts at discounted pricing without the ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... to develop a vaccine or drug treatment. In an effort to better understand ... publicly released the world’s largest imaging dataset portraying therapeutic compound effects from over ...
Breaking Biology Technology:
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient ... that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of ... 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, ... the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga ... supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with ...
Breaking Biology News(10 mins):